LB Pharmaceuticals

NMQ:LBRX · US50180M1080

PharmaceuticalsSmall

360° View

Value50

Price/Sales—

Price/Earnings71

Price/Book41

Dividend Yield1

Growth78

Revenue Growth—

Profit Growth40

Capital Growth95

TSR 52w74

Safety67

Leverage82

Liquidity3

Refinancing84

Combined72

Sentiment55

Analyst Opinions82

Pro Holdings57

Opinion Changes50

Market Pulse9

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2015

Employees2

Websitelbpharma.us

ISINUS50180M1080

Last UpdateApr 2, 2026

Index & Theme

PsychiatryNeurologyCentral Nervous SystemBiopharmaBiotechnologyPharmaceutical

Description

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company. The company is developing novel therapies for the treatment of a wide range of neuropsychiatric disorders, including schizophrenia, bipolar depression, adjunctive treatment of major d…

Analysis

LB Pharmaceuticals's 360° View rank of 79 places it among the strongest overall — better than 79% of its true peers.

It's a growth standout (78) and on the expensive side (50). On safety it is financially sound (67), and the market shows favorable sentiment (55). Taken together, its Combined rank of 72 reads as above its peer average.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare LB Pharmaceuticals with its peers

Neumora Therapeutics

NSQ:NMRA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

CalciMedica

NAQ:CALC

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

EyePoint

NMQ:EYPT

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

NRX Pharmaceuticals

NAQ:NRXP

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Pliant Therapeutics

NSQ:PLRX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Ventyx Biosciences

NSQ:VTYX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →